What are myeloproliferative neoplasms?
Myeloproliferative neoplasms (MPNs) are a group of chronic blood cancers that start in the bone marrow. A single blood-forming stem cell acquires a genetic change and begins to make too many mature blood cells – red cells, platelets, white cells, or a combination of these.
Unlike acute leukaemia, MPNs usually develop slowly. Many people live for many years, often decades, with regular check-ups and the right treatment.
The three “classic” MPNs are polycythaemia vera (PV, too many red cells), essential thrombocythaemia (ET, too many platelets) and primary myelofibrosis (PMF, scarring of the bone marrow). In American spelling these are polycythemia vera and essential thrombocythemia.
The main dangers are blood clots, an enlarged spleen, troublesome symptoms such as fatigue and itching and, in a minority of patients, progression to myelofibrosis or acute myeloid leukaemia.
1. Classification
Both current classifications – the 5th edition of the World Health Organization classification (WHO 2022) and the International Consensus Classification (ICC 2022) – group the following diseases under myeloproliferative neoplasms.
| MPN type | Main cells affected | Key genetic change(s) |
|---|---|---|
| Chronic myeloid leukaemia (CML) | Granulocytes (white cells) | BCR::ABL1 fusion (Philadelphia chromosome) in all cases |
| Polycythaemia vera (PV) | Mainly red cells, often also white cells and platelets | JAK2 V617F (~95 %); JAK2 exon 12 in most of the rest (~3–4 %) |
| Essential thrombocythaemia (ET) | Platelets | JAK2 V617F (~55–60 %), CALR (~20–25 %), MPL (~3–5 %); ~10–15 % “triple-negative” |
| Primary myelofibrosis (PMF), prefibrotic and overt | Megakaryocytes, with marrow scarring | JAK2 V617F (~60 %), CALR (~20–25 %), MPL (~5–8 %); ~10 % triple-negative |
| Chronic neutrophilic leukaemia (CNL) | Neutrophils | CSF3R mutations (usually T618I) in most cases |
| Chronic eosinophilic leukaemia (CEL) | Eosinophils | Various clonal mutations; no tyrosine-kinase gene fusion |
| Juvenile myelomonocytic leukaemia (JMML) – WHO only | Monocytes, in young children | RAS-pathway mutations (PTPN11, NRAS, KRAS, NF1, CBL) |
| MPN, not otherwise specified (MPN-NOS) | Mixed features | Variable |
CML is technically an MPN, but because it is driven by BCR::ABL1 and treated with tyrosine kinase inhibitors, it is usually discussed separately. PV, ET and PMF are therefore often called the BCR::ABL1-negative (or Philadelphia-negative) MPNs and are described in detail below.
Systemic mastocytosis was once grouped with the MPNs. Since 2016 it has been classified as a separate disease. Eosinophilic neoplasms with PDGFRA, PDGFRB or FGFR1 rearrangements also form their own category.
1.1 How common are MPNs?
The classic MPNs are rare. Each of PV and ET affects roughly 1–2 people per 100,000 each year, and PMF fewer than 1 per 100,000.
Most patients are diagnosed in their 60s. ET is the most common MPN in younger adults and is more frequent in women. PMF tends to appear later, at a median age of about 65–70.
2. Causes and Molecular Biology
2.1 Where the disease starts
All classic MPNs arise from a mutated haematopoietic stem cell in the bone marrow. The mutation switches on a growth-signalling pathway called JAK-STAT permanently.
As a result, the stem cell and its descendants keep multiplying even without the normal hormonal signals, such as erythropoietin for red cells or thrombopoietin for platelets.
2.2 The three “driver” mutations
| Mutation | Approximate frequency | What it does |
|---|---|---|
| JAK2 V617F | PV ~95 %; ET ~55–60 %; PMF ~60 % | Constantly active JAK2 enzyme, independent of growth signals |
| JAK2 exon 12 | ~3–4 % of PV (almost all JAK2 V617F-negative cases) | Similar activation, mainly driving red-cell production |
| CALR (type 1 and type 2) | ET ~20–25 %; PMF ~20–25 % | Abnormal calreticulin binds and activates the thrombopoietin receptor (MPL) |
| MPL (W515L/K) | ET ~3–5 %; PMF ~5–8 % | Constantly active thrombopoietin receptor |
| Triple-negative (no JAK2, CALR or MPL) | ET ~10–15 %; PMF ~10 % | Other clonal mutations may be found on wider gene testing |
These driver mutations are acquired, not inherited. They are found in the abnormal stem cell and all the blood cells it produces.
Additional mutations – for example in ASXL1, EZH2, SRSF2, U2AF1, IDH1/2 or TP53 – are common in myelofibrosis. They are called “high-molecular-risk” mutations because they predict a worse outlook.
2.3 Risk factors
Most MPNs have no clear cause. Age is the main risk factor.
First-degree relatives of people with an MPN have a several-fold higher risk than the general population. A common inherited variant of the JAK2 gene (the “46/1 haplotype”) contributes to this. However, the absolute risk for relatives remains low, so routine screening of family members is not recommended.
3. How does it look?
MPNs cannot be seen from the outside in the way a skin tumour can. The disease “looks” like abnormal numbers of blood cells in a blood test and a crowded – or scarred – bone marrow under the microscope.
Some outward signs can appear. People with PV often have a red or ruddy face, red palms and bloodshot eyes. People with myelofibrosis may look pale and thin, with a swollen abdomen from a large spleen.
3.1 Blood test and blood smear
| Feature | PV | ET | PMF (early / prefibrotic) | PMF (advanced / overt) |
|---|---|---|---|---|
| Red cells | Raised haemoglobin and haematocrit; cells often small (microcytic) because of iron deficiency | Normal | Normal or mildly reduced | Anaemia; teardrop-shaped cells (dacrocytes) and nucleated red cells |
| White cells | Often mildly raised; basophils sometimes increased | Normal or mildly raised | Often raised | Raised or low; immature cells (myelocytes, a few blasts) in the blood |
| Platelets | Often raised | Persistently ≥ 450 ×10⁹/L, sometimes > 1,000 ×10⁹/L; large platelets | Often raised, sometimes markedly | Often low in late disease |
| Other clues | Low serum erythropoietin (EPO); low ferritin is common | Normal EPO | LDH may be raised | Raised LDH and uric acid; “leukoerythroblastic” blood picture |
The combination of immature white cells and nucleated red cells in the blood is called a leukoerythroblastic picture. Together with teardrop cells, it suggests that the marrow is scarred and blood is being made in the spleen and liver instead (extramedullary haematopoiesis).
3.2 Bone marrow biopsy
| Finding | PV | ET | PMF |
|---|---|---|---|
| Cellularity | Hypercellular for age, with growth of all three cell lines (“panmyelosis”) | Normal or mildly increased | Early: hypercellular; late: patchy and reduced, replaced by fibrosis |
| Megakaryocytes (platelet-forming cells) | Increased, varied in size (pleomorphic) but mature | Increased, large and mature with deeply lobed (“staghorn”) nuclei, loosely clustered | Increased and atypical (abnormal nuclei, tight clusters) |
| Fibrosis (reticulin grade) | Usually none or mild (grade 0–1) | None or minimal (grade 0–1) | Prefibrotic: grade 0–1; overt PMF: grade 2–3 |
| Iron stores | Usually reduced or absent | Usually normal | Variable |
In plain language: under the microscope, the blood of a person with PV is “too full” of red cells. ET shows a flood of platelets.
In myelofibrosis, the marrow is trying to make blood cells but is gradually replaced by scar-like tissue. This produces odd-shaped red cells and often a large spleen.
4. Symptoms
Many people with an MPN have no symptoms at diagnosis. The disease is often found by chance on a routine blood test.
When symptoms do occur, they come from three main sources:
- Thickened blood and blood clots (thrombosis).
- Inflammatory signalling and high cell turnover, causing fatigue, sweats and weight loss.
- An enlarged spleen or, in late disease, failing bone marrow.
4.1 General (constitutional) symptoms
| Symptom | How common | Why it happens |
|---|---|---|
| Fatigue | The most frequent complaint in all MPNs | Inflammatory cytokines; anaemia in myelofibrosis |
| Itching (pruritus), typically after a warm bath or shower | Common in PV (around 40–50 %); less common in ET and PMF | Release of histamine and other substances from abnormal blood cells |
| Night sweats and low-grade fever | Common in myelofibrosis | Inflammatory cytokines |
| Unintentional weight loss | Mainly in myelofibrosis | High metabolic rate, early satiety from a large spleen |
| Bone or muscle pain | Mainly in myelofibrosis | Marrow expansion and inflammation |
| Difficulty concentrating, low mood, sleep problems | Common, often under-recognised | Symptom burden and inflammation |
Doctors often record these complaints with the MPN Symptom Assessment Form Total Symptom Score (MPN-SAF TSS, or MPN-10). It is a short questionnaire that helps track how symptoms change with treatment.
4.2 Blood clots and bleeding
Thrombosis is the main cause of illness and death in PV and ET. Clots can occur in arteries or veins, and sometimes form the first sign of the disease.
- Arterial clots – stroke, transient ischaemic attack, heart attack, or blocked leg arteries.
- Venous clots – deep vein thrombosis and pulmonary embolism.
- Clots in unusual places – the abdominal veins (Budd-Chiari syndrome, portal or mesenteric vein thrombosis). An MPN is one of the most common underlying causes of these clots, especially in younger women.
- Microvascular symptoms – headaches, visual disturbances, dizziness, and erythromelalgia (burning pain and redness in the hands and feet, relieved by cooling and by aspirin).
Bleeding is less common. It occurs mainly when platelet counts are extremely high (usually above 1,000–1,500 ×10⁹/L).
At such counts the platelets absorb large von Willebrand factor molecules from the blood, causing acquired von Willebrand syndrome. Aspirin can make this bleeding worse, so doctors check for it before starting aspirin in patients with very high platelet counts. In late myelofibrosis, bleeding is more often due to a low platelet count.
4.3 Enlarged spleen and liver
| Finding | Typical symptoms | Most often seen in |
|---|---|---|
| Splenomegaly (enlarged spleen) | Fullness or pain in the upper left abdomen, feeling full after small meals, pain in the left shoulder | PMF (most patients, sometimes massive); PV (about a third); ET (a minority) |
| Hepatomegaly (enlarged liver) | Abdominal swelling or discomfort | Mainly myelofibrosis |
A very large spleen can trap blood cells and worsen anaemia and low platelets. Blood flow through it can also raise pressure in the portal vein.
4.4 Other complications
- Gout and kidney stones – from raised uric acid due to high cell turnover.
- Secondary myelofibrosis – after many years, PV or ET can progress to scarring of the marrow (post-PV or post-ET myelofibrosis). Signs include a growing spleen, falling blood counts and new constitutional symptoms.
- Transformation to acute leukaemia (blast phase) – blasts of 20 % or more in the blood or marrow. This is uncommon in PV and ET (a few per cent over 10–20 years) and more frequent in PMF (roughly 10–20 % over 10 years). Warning signs are rising blasts, worsening anaemia or platelets, and rapid weight loss or fevers.
The outlook after transformation is poor, with a median survival of only months. A stem-cell transplant offers the best chance of long-term control in suitable patients.
5. Diagnosis
Diagnosis combines the blood count, a careful search for other (reactive) causes, gene testing and usually a bone marrow biopsy.
5.1 First tests
| Test | Typical findings | Why it matters |
|---|---|---|
| Full blood count and blood smear | Raised haemoglobin, platelets or white cells; teardrop cells and immature cells in myelofibrosis | Shows which cell line is affected |
| Serum erythropoietin (EPO) | Low in PV; normal or high in secondary erythrocytosis | Separates PV from other causes of a high red-cell count |
| Iron studies (ferritin, transferrin saturation) | Iron deficiency is common in PV; iron deficiency can also cause reactive thrombocytosis | Iron deficiency can hide PV and mimic ET |
| LDH and uric acid | Often raised, especially in myelofibrosis | Markers of cell turnover |
| JAK2 V617F test (blood) | Positive in most PV and over half of ET and PMF | Confirms a clonal disorder |
| CALR and MPL tests, then exon 12 if needed | Explain most JAK2-negative ET and PMF; exon 12 covers most JAK2 V617F-negative PV | Completes the driver-mutation picture |
| BCR::ABL1 test | Must be negative | Rules out CML, which is treated differently |
| Next-generation sequencing (NGS) panel | High-risk mutations such as ASXL1, SRSF2, U2AF1, EZH2, IDH1/2, TP53 | Prognosis, especially in myelofibrosis and triple-negative cases |
Common reactive causes of high blood counts must be excluded. They include smoking, sleep apnoea, lung or heart disease, kidney tumours and testosterone treatment (for high red cells), and iron deficiency, infection, inflammation, surgery or a removed spleen (for high platelets).
5.2 Bone marrow examination
A bone marrow aspirate and trephine biopsy, usually from the back of the hip bone, shows cellularity, megakaryocyte shape and the degree of fibrosis. Special stains (reticulin and trichrome) grade the scarring from 0 to 3.
Chromosome testing (karyotype) of the marrow adds prognostic information, especially in myelofibrosis. In myelofibrosis the aspirate is often a “dry tap” because the marrow is too scarred to draw up.
5.3 WHO 2022 diagnostic criteria (summary)
| Disease | Major criteria | Minor criteria | Diagnosis requires |
|---|---|---|---|
| PV | 1. Haemoglobin > 16.5 g/dL (men) or > 16.0 g/dL (women), or haematocrit > 49 % (men) or > 48 % (women), or red-cell mass > 25 % above predicted. 2. Bone marrow hypercellular for age with growth of all three lines (panmyelosis), including pleomorphic mature megakaryocytes. 3. JAK2 V617F or JAK2 exon 12 mutation. |
Subnormal serum EPO | All 3 major, or major 1 + 2 and the minor criterion |
| ET | 1. Platelets ≥ 450 ×10⁹/L. 2. Bone marrow with mainly megakaryocyte proliferation (large, mature, hyperlobated forms); no significant increase in granulocyte or red-cell production; fibrosis at most grade 1. 3. Criteria for CML, PV, PMF, MDS or other myeloid neoplasms not met. 4. JAK2, CALR or MPL mutation. |
Another clonal marker, or no evidence of reactive thrombocytosis | All 4 major, or the first 3 major and the minor criterion |
| Overt PMF | 1. Megakaryocyte proliferation and atypia with reticulin and/or collagen fibrosis grade 2 or 3. 2. Criteria for ET, PV, CML, MDS or other myeloid neoplasms not met. 3. JAK2, CALR or MPL mutation, or another clonal marker, or no reactive myelofibrosis. |
1. Anaemia not due to another condition. 2. White cells ≥ 11 ×10⁹/L. 3. Palpable splenomegaly. 4. LDH above the upper normal limit. 5. Leukoerythroblastosis. |
All 3 major and at least 1 minor criterion (confirmed on two consecutive tests) |
Prefibrotic PMF has the same molecular findings and atypical megakaryocytes but fibrosis of grade 0–1. It is easily mistaken for ET. The distinction matters because prefibrotic PMF carries a higher risk of progression to overt myelofibrosis and leukaemia.
The ICC 2022 criteria are very similar. In borderline PV cases, bone marrow findings are the deciding factor; formal red-cell mass measurement is now rarely used.
6. Risk Stratification
Risk scores guide when to start cytoreductive (count-lowering) treatment and who should be considered for a stem-cell transplant.
| Disease | Score | What it includes |
|---|---|---|
| PV – thrombosis risk | Conventional two-tier model (ELN, NCCN) | High risk: age ≥ 60 years and/or previous thrombosis. Low risk: neither. Cardiovascular risk factors are treated in all patients. |
| PV – survival | Mayo/IWG-PV score | Age, white-cell count ≥ 15 ×10⁹/L, previous venous thrombosis, abnormal karyotype |
| ET – thrombosis risk | Revised IPSET-thrombosis | Age > 60 years, previous thrombosis and JAK2 V617F → very low, low, intermediate and high risk |
| PMF – survival at diagnosis | IPSS | Age > 65, haemoglobin < 10 g/dL, white cells > 25 ×10⁹/L, blood blasts ≥ 1 %, constitutional symptoms |
| PMF – survival at any time | DIPSS and DIPSS-plus | DIPSS uses the IPSS factors at any point in the disease; DIPSS-plus adds unfavourable karyotype, platelets < 100 ×10⁹/L and transfusion need |
| PMF – molecular scores | MIPSS70, MIPSS70+ v2.0, GIPSS | Combine clinical factors with karyotype and high-risk mutations (e.g. ASXL1, SRSF2, U2AF1 Q157, absence of CALR type 1) |
| Post-PV/post-ET myelofibrosis | MYSEC-PM | Age, haemoglobin, platelets, blood blasts, constitutional symptoms and CALR status |
7. Treatment
There is no medicine that cures PV, ET or PMF. The goals of treatment are to:
- Prevent blood clots and bleeding.
- Control symptoms and spleen size.
- Delay or prevent progression to myelofibrosis or acute leukaemia.
- Improve survival, with allogeneic stem-cell transplantation as the only potentially curative option.
7.1 Treatments used across MPNs
| Treatment | When it is used | Comments |
|---|---|---|
| Low-dose aspirin (usually 75–100 mg daily) | Nearly all PV patients; most ET patients | Reduces clot risk and erythromelalgia. May be omitted in very-low-risk ET; avoided until acquired von Willebrand syndrome is excluded when platelets are very high |
| Venesection (phlebotomy) | All PV patients | Removes about 250–500 mL of blood at a time, initially every few days to weekly, then as needed to keep haematocrit < 45 % |
| Hydroxyurea (hydroxycarbamide) | First-line cytoreduction for high-risk PV and ET; also for symptoms in some MF patients | Oral tablet; dose adjusted to blood counts. Side effects include mouth and leg ulcers and skin cancers with long-term use |
| Interferon alfa (ropeginterferon alfa-2b, peginterferon alfa-2a) | PV and ET, especially younger patients and in pregnancy | Ropeginterferon alfa-2b is approved for PV (EU 2019, FDA 2021). Can reduce the JAK2 mutation burden. Side effects include flu-like symptoms, low mood and thyroid problems |
| Anagrelide | ET when hydroxyurea is not tolerated or ineffective | Lowers platelets only. Can cause palpitations, headache and fluid retention |
| Busulfan | Older patients with PV or ET, as a later-line option | Used rarely because of leukaemia risk with long-term use |
| JAK inhibitors | Myelofibrosis with a large spleen or symptoms; PV resistant to or intolerant of hydroxyurea (ruxolitinib) | See section 7.4 |
| Allogeneic stem-cell transplant | Intermediate-2 or high-risk (and selected intermediate-1) myelofibrosis; blast phase | Only curative option; significant risk of complications and death, so careful selection is essential |
7.2 Polycythaemia vera
| Situation | First-line approach | Other options |
|---|---|---|
| Low risk (age < 60 and no previous thrombosis) | Venesection to haematocrit < 45 % + low-dose aspirin | Ropeginterferon if venesection is poorly tolerated, symptoms are troublesome, the spleen enlarges or counts keep rising |
| High risk (age ≥ 60 and/or previous thrombosis) | Venesection + aspirin + cytoreduction with hydroxyurea or ropeginterferon alfa-2b | Ruxolitinib if hydroxyurea fails or is not tolerated |
| Itching that persists despite antihistamines | Ruxolitinib or interferon | Narrow-band UVB phototherapy; SSRIs such as paroxetine |
The haematocrit target of below 45 % comes from the CYTO-PV trial. Patients kept below 45 % had about a four-fold lower rate of cardiovascular death and major clots than those kept at 45–50 %.
Iron deficiency from venesection is expected in PV and actually helps to limit red-cell production. Iron supplements are usually avoided unless symptoms of iron deficiency are severe.
7.3 Essential thrombocythaemia
| Risk group (revised IPSET-thrombosis) | Usual approach |
|---|---|
| Very low (age ≤ 60, no thrombosis, JAK2-negative) | Observation; aspirin optional, especially in CALR-mutated disease |
| Low (age ≤ 60, no thrombosis, JAK2-positive) | Low-dose aspirin |
| Intermediate (age > 60, no thrombosis, JAK2-negative) | Aspirin; cytoreduction considered case by case |
| High (previous thrombosis, or age > 60 with JAK2 mutation) | Cytoreduction (hydroxyurea first-line; interferon in younger patients) + aspirin. Anticoagulation for previous venous clots |
Anagrelide is a second-line choice. In the UK PT-1 trial, hydroxyurea plus aspirin prevented arterial clots and myelofibrosis better than anagrelide plus aspirin.
CALR-mutated ET has a lower clot risk than JAK2-mutated ET. Many patients with low-risk CALR-mutated disease need no treatment beyond monitoring.
7.4 Myelofibrosis (primary, post-PV and post-ET)
| Situation | First-line approach | Other options |
|---|---|---|
| Lower risk, few symptoms | Observation with regular checks | Hydroxyurea or interferon for high counts in selected patients |
| Large spleen or troublesome symptoms, platelets ≥ 50 ×10⁹/L | Ruxolitinib (FDA 2011) or fedratinib (FDA 2019) | Momelotinib if anaemia is a major problem |
| Platelets < 50 ×10⁹/L | Pacritinib (FDA 2022) | Clinical trial |
| Anaemia dominant | Momelotinib (FDA 2023), erythropoiesis-stimulating agents (if EPO is low), danazol | Thalidomide or lenalidomide (with prednisone), luspatercept (under study), transfusions |
| Intermediate-2/high-risk disease, fit patient | Referral for allogeneic stem-cell transplant | Often bridged with a JAK inhibitor |
| Accelerated or blast phase (10–19 % or ≥ 20 % blasts) | Hypomethylating agents (azacitidine, decitabine) ± venetoclax, or intensive chemotherapy, followed by transplant if possible | Clinical trial; supportive and palliative care |
Ruxolitinib was the first JAK inhibitor. In the COMFORT-I trial, 42 % of patients on ruxolitinib achieved at least a 35 % reduction in spleen volume at 24 weeks, compared with less than 1 % on placebo, and symptoms improved markedly.
JAK inhibitors shrink the spleen and improve symptoms, but they rarely eliminate the disease. Common side effects include anaemia and low platelets, infections (including shingles) and, with fedratinib, a risk of a serious brain disorder from thiamine (vitamin B1) deficiency, so thiamine levels are checked.
New treatments under study include BET inhibitors (pelabresib), the telomerase inhibitor imetelstat, navtemadlin, mutant-CALR antibodies and combinations with JAK inhibitors.
7.5 Monitoring
Blood counts are checked every few weeks while treatment is being adjusted, then every 3–6 months once stable. Spleen size is followed by examination or ultrasound, and symptoms by the MPN-SAF score.
Doctors watch for signs of progression: a growing spleen, falling haemoglobin or platelets, rising white cells or blasts, and new constitutional symptoms.
8. Outlook (Prognosis)
The outlook differs considerably between the three classic MPNs. In a large Mayo Clinic series, median survival was about 20 years for ET, 14 years for PV and 6 years for PMF, with much longer survival in patients diagnosed before age 60.
Many people with ET and low-risk PV have a life expectancy close to that of the general population. In myelofibrosis, survival varies widely with the risk score – from a few years in high-risk disease to well over a decade in low-risk patients.
The main causes of death are blood clots and cardiovascular disease in PV and ET, and progression to marrow failure or acute leukaemia in myelofibrosis.
9. Living with an MPN
9.1 Everyday life
| Recommendation | Why |
|---|---|
| Stop smoking | Smoking is a major, avoidable cause of clots |
| Control blood pressure, cholesterol, diabetes and weight | Cardiovascular risk factors add to the clot risk from the MPN |
| Stay active with regular, moderate exercise | Improves fitness, mood and fatigue |
| Drink enough fluids, especially after venesection and on long journeys | Dehydration thickens the blood |
| Move regularly on long flights and consider compression stockings | Reduces the risk of deep vein thrombosis |
| Keep vaccinations up to date (influenza, pneumococcal, COVID-19; shingles vaccine for people on JAK inhibitors) | JAK inhibitors and some other treatments increase the risk of infection |
| Check before taking NSAIDs (such as ibuprofen) or supplements | They can increase bleeding risk, especially with aspirin |
| Use lukewarm water and pat the skin dry if bathing triggers itching | Reduces water-induced itching in PV |
9.2 Emotional support
Living with a chronic blood cancer can be tiring and stressful, even when the outlook is good. Fatigue and uncertainty about the future often weigh more heavily than the disease itself.
Patient organisations such as the MPN Research Foundation and MPN Voice, together with peer support groups and psychological counselling, can help.
For people with higher-risk myelofibrosis, early conversations about goals of care and transplant are valuable.
9.3 Pregnancy
Pregnancy in women with an MPN is possible but carries a higher risk of miscarriage, clots and placental problems. It should be planned and managed jointly by a haematologist and an obstetrician.
- Low-dose aspirin is usually recommended throughout pregnancy unless there is a bleeding risk.
- Low-molecular-weight heparin is added for women with previous clots or other high-risk features, and is usually continued for about 6 weeks after delivery.
- Interferon is the cytoreductive treatment of choice in pregnancy.
- Hydroxyurea, anagrelide and JAK inhibitors should be stopped before conception because they may harm the baby.
10. Frequently Asked Questions
| Question | Answer |
|---|---|
| Is an MPN a cancer? | Yes. MPNs are classified as chronic blood cancers because they arise from a clone of abnormal stem cells. Most behave as long-term conditions rather than aggressive cancers. |
| Can MPNs be cured? | Only an allogeneic stem-cell transplant can cure an MPN. It is mainly offered to people with higher-risk myelofibrosis. Most patients live for many years with treatment that controls the disease. |
| Should my family be tested? | Usually not. The driver mutations are acquired, not inherited. Relatives have a slightly higher risk than average, but routine screening is not recommended. |
| Will I develop leukaemia? | The risk is low in PV and ET – a few per cent over 10–20 years. It is higher in myelofibrosis, roughly 10–20 % over 10 years. Regular monitoring helps detect changes early. |
| Can I take iron supplements? | In PV, iron usually fuels red-cell production and is avoided unless your haematologist recommends it. In ET and myelofibrosis, iron is given only if a deficiency is confirmed. |
| Is it safe to travel? | Yes, with precautions: drink plenty of fluids, move your legs during long journeys, carry a summary of your diagnosis and medicines, and take enough medication with you. |
11. Summary
Myeloproliferative neoplasms are chronic blood cancers in which the bone marrow makes too many blood cells. Most cases are driven by mutations in JAK2, CALR or MPL that switch on the JAK-STAT growth pathway.
Many patients have no symptoms at diagnosis. The main risks are blood clots, symptom burden and, especially in myelofibrosis, marrow failure or transformation to acute leukaemia.
Diagnosis rests on blood counts, gene testing (including a negative BCR::ABL1 test) and a bone marrow biopsy interpreted according to the WHO 2022 or ICC 2022 criteria.
Treatment is tailored to the risk group. Options range from venesection and aspirin to hydroxyurea, interferon and JAK inhibitors, while allogeneic stem-cell transplantation remains the only curative option for selected patients with myelofibrosis.
Resources
- Khoury, J.D. et al. (2022) ‘The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms’, Leukemia, 36(7), pp. 1703-1719.
- Arber, D.A. et al. (2022) ‘International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data’, Blood, 140(11), pp. 1200-1228.
- Tefferi, A. (2023) ‘Primary myelofibrosis: 2023 update on diagnosis, risk-stratification, and management’, American Journal of Hematology, 98(5), pp. 801-821.
- Tefferi, A. and Barbui, T. (2023) ‘Polycythemia vera: 2024 update on diagnosis, risk-stratification, and management’, American Journal of Hematology, 98(9), pp. 1465-1487.
- Barbui, T. et al. (2012) ‘Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis)’, Blood, 120(26), pp. 5128-5133.
- Verstovsek, S. et al. (2012) ‘A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis’, New England Journal of Medicine, 366(9), pp. 799-807.
- Marchioli, R. et al. (2013) ‘Cardiovascular events and intensity of treatment in polycythemia vera’, New England Journal of Medicine, 368(1), pp. 22-33.
- National Cancer Institute (2026) Myeloproliferative Neoplasms Treatment (PDQ®) – Health Professional Version. Available at: https://www.cancer.gov/types/myeloproliferative/hp/myeloproliferative-neoplasms-treatment (Accessed: October 2026).
- MPN Research Foundation (2026) Understanding MPNs. Available at: https://www.mpnresearchfoundation.org/understanding-mpns/ (Accessed: October 2026).
Prepared by the editorial team, October 2026.